Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Gleave

Showing results (221-230 of 260) with videos related to

Pageof 26
Sort By:
Carcinogenesis|August 31, 2018
Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal diseaseThomas U Ahearn, Sam Peisch, Andreas Pettersson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2020
Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate CancerXiangnan Guan, Duanchen Sun, Eric Lu, et al.
The New England Journal of Medicine|June 1, 2026
Perioperative Apalutamide in High-Risk Localized Prostate CancerMary-Ellen Taplin, Martin Gleave, Neal D Shore, et al.
Journal of Medicinal Chemistry|September 23, 2011
Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonistsChuangxing Guo, Angelica Linton, Susan Kephart, et al.
Molecular Cancer Therapeutics|January 19, 2012
Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor targetColin C Collins, Stanislav V Volik, Anna V Lapuk, et al.
Oncotarget|February 2, 2017
Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistanceMannan Nouri, Josselin Caradec, Amy Anne Lubik, et al.
European Urology|December 21, 2017
Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants MeetingJun Luo, Gerhardt Attard, Steven P Balk, et al.
Human Pathology|February 17, 2022
Development and validation of a quantitative reactive stroma biomarker (qRS) for prostate cancer prognosisSamuel Ruder, Yan Gao, Yi Ding, et al.
Advances in Anatomic Pathology|December 13, 2012
A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue MicroarraySarah Hawley, Ladan Fazli, Jesse K McKenney, et al.
Nature Cell Biology|September 7, 2021
An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancerAlastair Davies, Shaghayegh Nouruzi, Dwaipayan Ganguli, et al.
Pageof 26

Showing results (221-230 of 260) with videos related to

Sort By:
Pageof 26
Carcinogenesis|August 31, 2018
Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal diseaseThomas U Ahearn, Sam Peisch, Andreas Pettersson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2020
Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate CancerXiangnan Guan, Duanchen Sun, Eric Lu, et al.
The New England Journal of Medicine|June 1, 2026
Perioperative Apalutamide in High-Risk Localized Prostate CancerMary-Ellen Taplin, Martin Gleave, Neal D Shore, et al.
Journal of Medicinal Chemistry|September 23, 2011
Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonistsChuangxing Guo, Angelica Linton, Susan Kephart, et al.
Molecular Cancer Therapeutics|January 19, 2012
Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor targetColin C Collins, Stanislav V Volik, Anna V Lapuk, et al.
Oncotarget|February 2, 2017
Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistanceMannan Nouri, Josselin Caradec, Amy Anne Lubik, et al.
European Urology|December 21, 2017
Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants MeetingJun Luo, Gerhardt Attard, Steven P Balk, et al.
Human Pathology|February 17, 2022
Development and validation of a quantitative reactive stroma biomarker (qRS) for prostate cancer prognosisSamuel Ruder, Yan Gao, Yi Ding, et al.
Advances in Anatomic Pathology|December 13, 2012
A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue MicroarraySarah Hawley, Ladan Fazli, Jesse K McKenney, et al.
Nature Cell Biology|September 7, 2021
An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancerAlastair Davies, Shaghayegh Nouruzi, Dwaipayan Ganguli, et al.
Pageof 26